Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trialHaruhiro Saito, Makoto Maemondo, Tatsuro Fukuhara et al.|The Lancet Oncology|2019Cited by 636
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase InhibitorHiroaki Akamatsu, Nobuyuki Yamamoto, Naoko Miura et al.|JAMA Oncology|2021Cited by 185
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L StudyHirotsugu Kenmotsu, Toshiaki Takahashi, Kazushige Wakuda et al.|Journal of Thoracic Oncology|2022Cited by 158
FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitorKoichi Azuma, Tomoaki Hoshino|Oncotarget|2014Cited by 108
Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate modelKoichi Azuma, Tomoaki Hoshino|Journal for ImmunoTherapy of Cancer|2022Cited by 42